Lattice Biologics Ltd. (LBLTF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.21: the stock has moved about 21% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerLattice Biologics Ltd. (LBLTF) trades at $0.0001. Lattice Biologics Ltd. is a biotech company specializing in biologic products for bone regeneration across various medical applications. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for LBLTF: LBLTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Lattice Biologics Ltd. (LBLTF) Healthcare & Pipeline Overview
Lattice Biologics Ltd. is a pioneering biotech firm focused on developing and marketing biologic products for bone regeneration, leveraging innovative amniotic fluid technology to address diverse orthopedic and dental needs globally.
What Is the Investment Thesis for LBLTF?
Lattice Biologics Ltd. presents a unique investment thesis driven by its innovative product line and expanding market opportunities in the healthcare sector. The company has reported a gross margin of 41.4%, indicating a strong potential for profitability as it scales its operations. With a negative profit margin of -60.2%, the company is currently in a growth phase, focusing on increasing its market share in the bone regeneration space. The ongoing development of its amniotic fluid-based products is expected to drive revenue growth, particularly in orthopedic and dental markets, which are projected to grow significantly over the next few years. Additionally, the company's diverse product range, including traditional allografts, positions it favorably against competitors. However, potential risks such as regulatory challenges and market competition must be carefully monitored. Overall, Lattice Biologics Ltd. is well-positioned to capitalize on emerging trends in the healthcare sector, making it a noteworthy entity for investors seeking exposure to biotech innovations.
Based on FMP financials and quantitative analysis
LBLTF Key Highlights
Market Cap: $0.00B, indicating a currently unvalued or inactive trading status.
- Profit Margin: -60.2%, reflecting ongoing investment in growth and development.
- Gross Margin: 41.4%, showcasing efficiency in production and potential for future profitability.
- Beta: 1.21, suggesting higher volatility compared to the market average.
- Dividend Yield: None, as the company does not currently distribute dividends.
Who Are LBLTF's Competitors?
LBLTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| SNN Smith & Nephew plc | $26.97 | +2.08% | $11.3B | 87 5-pillar |
| ABMD Abiomed, Inc. | $381.02 | 0.00% | $17.2B | — |
| ISRG Intuitive Surgical, Inc. | $406.48 | +3.71% | $144B | 94 5-pillar |
| BJDX Bluejay Diagnostics, Inc. | $0.76 | -9.01% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $8.10 | +0.75% | $5.63M | 30 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.74 | -1.09% | $31.4M | — |
| SNWV SANUWAVE Health, Inc. | $4.82 | +4.33% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.92 | -2.01% | $48.1M | 31 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LBLTF's Key Strengths?
Innovative product line with unique amniotic fluid-based solutions.
- Strong gross margin of 41.4%, indicating operational efficiency.
- Diverse range of applications across multiple medical disciplines.
- Established presence in the growing orthopedic and dental markets.
What Are LBLTF's Weaknesses?
Negative profit margin of -60.2%, indicating financial challenges.
- Limited market capitalization, affecting visibility and investment appeal.
- Dependence on a niche market, which may limit growth potential.
- Potential regulatory hurdles in the biotech industry.
What Are the Key Risks for LBLTF?
Financial-distress signal — its Altman Z-Score of -25.57 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges that could delay product approvals.
- Competitive pressures from established medical device companies.
- Market volatility affecting investor sentiment and stock performance.
- Dependence on a niche market may limit growth opportunities.
What Threats Does LBLTF Face?
- Intense competition from established medical device companies.
- Regulatory challenges that may impact product approval timelines.
- Market volatility affecting investment and operational stability.
- Rapid technological advancements requiring continuous innovation.
What Are LBLTF's Competitive Advantages?
- Innovative product offerings that differentiate Lattice Biologics from competitors.
- Strong focus on research and development to stay ahead in the market.
- Established relationships with healthcare providers and institutions.
- Specialization in amniotic fluid-based products, a unique niche in the industry.
- Commitment to enhancing patient outcomes through advanced technologies.
What Does LBLTF Do?
Founded in Belgrade, Montana, Lattice Biologics Ltd. is a biotech company dedicated to the development, manufacture, and marketing of biologic products aimed at enhancing bone regeneration in dental, spine, and orthopedic applications. The company has carved a niche in the medical devices sector with its innovative products, including AmnioBoost and AmnioBlast, which are derived from amniotic fluid. These products are designed to support various medical procedures such as spine surgery, breast reconstruction, and orthopedic surgeries, demonstrating versatility in their application. Lattice Biologics also offers a comprehensive range of traditional allografts, including demineralized bone matrix allografts, which are crucial for enhancing surgical outcomes in complex procedures. The company’s commitment to advancing medical technology is evident in its continuous efforts to improve patient care through innovative solutions. With a global reach, Lattice Biologics serves a diverse clientele, addressing critical needs in bone regeneration and healing across multiple medical disciplines. The company’s strategic focus on research and development positions it well within the competitive landscape, as it seeks to expand its product offerings and enhance its market presence.
What Products and Services Does LBLTF Offer?
- Develop biologic products for bone regeneration in dental, spine, and orthopedic applications.
- Manufacture innovative amniotic fluid-based products such as AmnioBoost and AmnioBlast.
- Provide a range of allografts including traditional, spinal, and demineralized bone matrix.
- Market products for various surgical procedures including spine surgery and breast reconstruction.
- Focus on enhancing patient outcomes through advanced medical technologies.
- Serve a global clientele in the healthcare sector.
How Does LBLTF Make Money?
- Generate revenue through the sale of biologic products and allografts.
- Leverage innovative product development to meet the needs of healthcare providers.
- Engage in partnerships with hospitals and clinics for product distribution.
- Focus on research and development to expand the product portfolio.
- Utilize marketing strategies to promote the benefits of biologic solutions.
What Industry Does LBLTF Operate In?
The medical devices industry is experiencing robust growth, driven by advancements in technology and an increasing demand for innovative healthcare solutions. The global market for orthopedic devices is projected to reach approximately $60 billion by 2027, reflecting a compound annual growth rate (CAGR) of around 5%. Lattice Biologics Ltd. operates within this expanding market, focusing on biologic products that enhance bone regeneration—a critical area in orthopedic and dental surgery. The competitive landscape includes established players and emerging biotech firms, with Lattice Biologics differentiating itself through its unique amniotic fluid-based offerings. This strategic positioning allows the company to tap into niche markets and leverage growing trends in regenerative medicine.
Who Are LBLTF's Key Customers?
- Healthcare providers including hospitals and surgical centers.
- Dental professionals seeking advanced solutions for implant procedures.
- Orthopedic surgeons focusing on innovative treatments for bone regeneration.
- Sports medicine practitioners addressing injuries and rehabilitation.
- Patients requiring surgical interventions for various medical conditions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Lattice Biologics Ltd. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Belgrade, US. The company is led by CEO Donna Medina. LBLTF has traded publicly since 2010.
Financial Health
Lattice Biologics Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -25.57 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Lattice Biologics Ltd. revenue of about $9.5M for fiscal 2026, with EPS near $-0.03.
LBLTF Latest News
No recent news available for LBLTF.
LBLTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LBLTF.
Price Targets
Wall Street price target analysis for LBLTF.
LBLTF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LBLTF; grades run from A+ (80-100) to F (below 30).
Leadership: Donna Medina
CEO
Donna Medina has a robust background in the biotech industry, with extensive experience in product development and strategic management. She has held various leadership roles in healthcare companies, focusing on innovation and market expansion. With a strong educational foundation in life sciences, Medina has been instrumental in driving Lattice Biologics Ltd.'s vision and growth.
Track Record: Under Donna Medina's leadership, Lattice Biologics has launched key products that have expanded its market presence. Her strategic decisions have focused on enhancing R&D capabilities and fostering partnerships within the healthcare sector.
LBLTF OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher-tier listings like OTCQX or OTCQB, often resulting in less visibility and liquidity. These companies may have limited financial disclosures, making it essential for investors to conduct thorough due diligence.
- OTC Tier: OTC Other
- Limited financial disclosures may lead to challenges in assessing the company's performance.
- Lower liquidity can result in higher volatility and difficulty in executing trades.
- Regulatory scrutiny may be heightened for companies in the OTC market.
- Market perception issues may arise due to the company's tier classification.
- Review the company's financial statements and disclosures.
- Assess the competitive landscape and market positioning.
- Evaluate the management team's experience and track record.
- Investigate product development pipelines and regulatory status.
- Monitor industry trends and potential market opportunities.
- Established product offerings in the healthcare sector.
- Presence of experienced leadership with a background in biotech.
- Engagement in research and development to drive innovation.
Common Questions About LBLTF (Healthcare)
What are the main risks for LBLTF?
Lattice Biologics Ltd. faces several risks, including regulatory challenges that may impact product approval timelines and market entry. The company also contends with intense competition from established players in the medical devices industry, which could affect its market share.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial disclosures may affect the assessment of the company's performance.